Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2016 · 10-Q
Revenue$1.86M$1.86M+143.3% vs Q1 2015 Net Income-$382.70K-$382.70KN/M vs Q1 2015 EPS Diluted-$0.03-$0.03N/M vs Q1 2015 Operating Income-$257,337N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Free Cash Flowderived-$549,008N/M Margins · derivedOperating margin-13.8%+136.7 pt vs Q1 2015
Net margin-20.6%+136.7 pt vs Q1 2015
ended Jun 30, 2015 · filed Aug 14, 2015 · 45 d after period end